Benchmark Robust & Standardized Processes for Streamlined Raw Material Management

Cell and gene therapies are advancing into late-stage development and commercialization, where raw materials have become a critical determinant of whether programs succeed or fail. Small inconsistencies that once went unnoticed are now triggering regulatory scrutiny, inflating cost of goods, and causing delays that put timelines and patient access at risk.

Following the sunshine to San Diego, the 3rd Raw Materials for Cell & Gene Therapy Summit was the only dedicated forum designed to help you take control of this risk. Through technical case studies and cross-functional discussion, attendees uncovered practical, phase-appropriate strategies to manage variability, strengthen supplier qualification, and build raw material frameworks that scale confidently from early development through to commercial manufacturing.

By joining leading experts across quality, MSAT, supply chain, and process development, attendees engaged in face-to-face discussions on how peers were defining material specifications, managing lot-to-lot variability, and making critical qualification decisions under real development pressure.

This collaborative environment enabled open, candid exchange that simply couldn't be replicated through reports or virtual formats. Attendees left with the clarity to make better decisions on raw material selection and supplier qualification, the confidence to defend them, and the relationships needed to accelerate their path to reliable, cost-effective, and scalable cell and gene therapy manufacturing.